|
|
|
|
Hydroxychloroquine trial begins in the UK
|
|
|
|
| Top Stories |
 |
|
|
|
IANS | 21 May, 2020
A trial to see whether two anti-malarial drugs -- chloroquine,
hydroxychloroquine -- could prevent the novel coronavirus has begun in
the UK's Brighton and Oxford.
The first UK participants in the
global trial are being enrolled on Thursday at the Brighton and Sussex
University Hospitals and the John Radcliffe Hospital in Oxford, reports
the BBC.
They will be given either hydroxychloroquine or a placebo for three months.
These are the first of a planned 25 UK sites, with results expected by the end of the year.
The
trial is open to anyone delivering direct care to coronavirus patients
in the UK, as long as they have not been diagnosed with COVID-19.
It will test whether the drugs can prevent healthcare workers exposed to the virus from contracting it.
One
of the study's leaders, Professor Nicholas White at the University of
Oxford said: "We really do not know if chloroquine or hydroxychloroquine
are beneficial or harmful against COVID-19."
But, he said, a
randomised controlled trial such as this one, where neither the
participant nor the researchers know who has been given the drug or a
placebo, was the best way to find out.
"A widely available, safe
and effective vaccine may be a long way off," the BBC quoted Professor
Martin Llewelyn from Brighton and Sussex Medical School, who is also
leading the study.
"If drugs as well-tolerated as chloroquine and
hydroxychloroquine could reduce the chances of catching COVID-19, this
would be incredibly valuable."
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Customs Exchange Rates |
| Currency |
Import |
Export |
US Dollar
|
₹91.35
|
89.65 |
UK Pound
|
₹125.3
|
₹121.3 |
Euro
|
₹108.5
|
₹104.85 |
| Japanese
Yen |
₹58.65 |
₹56.8 |
| As on 19 Feb, 2026 |
|
|
| Daily Poll |
 |
 |
| What is the biggest war impact on MSMEs? |
|
|
|
|
|
| Commented Stories |
|
|
|
|
|
|
| |
|
